Many people with obesity have tried lifestyle changes, but for some, those are not enough.
That’s where Saxenda (liraglutide) and Wegovy (semaglutide) can help. Both are prescription medications that belong to the same drug class and have transformed weight management for adults, and even for some teens.
But how do they differ? Which one keeps the weight off longer?
🔑 Key takeaways
|
Mechanism & dosing
Here’s how Wegovy and Saxenda work and why their dosing schedules differ:
How Saxenda works
Saxenda is a once-daily injection that contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a hormone the body naturally produces, called GLP-1. This hormone triggers the release of insulin, curbs appetite, and helps people feel full for longer periods. When appetite drops, it becomes easier to reduce calorie intake, which supports weight loss.
The same active ingredient is used in Victoza, a medication for type 2 diabetes, but the dosing is different. Saxenda is not interchangeable with Victoza because it is specifically designed for weight management. The medication is injected under the skin using a multi-use pen that contains several doses.
Dosing of Saxenda
The dosing starts at 0.6 mg daily, then gradually increases every week to 1.2 mg, 1.8 mg, 2.4 mg, and finally 3 mg daily as the maintenance dose.
It can be used by adults with a body mass index (BMI) of 30 or more, or 27 and above with at least one weight-related condition. It is also approved for adolescents aged 12 to 17 years who weigh more than 132 pounds.
How Wegovy works
Wegovy contains semaglutide, another GLP-1 receptor agonist that acts in a similar way — by reducing hunger and helping people feel fuller for longer.
The main difference lies in how long the medication stays active in the body.
- Wegovy remains effective for about 165 hours
- Saxenda lasts about 13 to 15 hours
This allows Wegovy to be taken once a week rather than every day.
Dosing of Wegovy
Wegovy comes in single-use pens with premeasured doses. The dose increases gradually to minimize side effects. The schedule begins with 0.25 mg weekly for the first month, followed by 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg weekly. Each pen is used once and discarded, making it simple and clean to use.
Both medications can be injected at any time of the day, with or without meals, and in the abdomen, thigh, or upper arm. Rotating injection sites helps prevent lumps under the skin.
| ✂️ In short The key difference is frequency. Saxenda users inject daily, while Wegovy users inject once weekly. Saxenda’s daily schedule might fit people who like routine, whereas Wegovy’s longer duration can feel easier for those who prefer fewer injections. Both are approved for people aged 12 years and older, with dose adjustments available if side effects occur. |
Which is more effective for weight loss, Saxenda and Wegovy?
Wegovy is more effective for weight loss, producing substantially greater and longer-lasting reductions in body weight than Saxenda across clinical trials and real-world studies.
Wegovy’s efficacy for weight loss
In the STEP 1 trial, adults receiving Wegovy lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Nearly 86% of participants taking Wegovy lost at least 5% of their body weight, while half achieved 15% or more.
Another head-to-head study compared the two medications directly. Participants taking Wegovy lost an average of 15.8% of their body weight, while those on Saxenda lost 6.4% over the same 68-week period. These results were supported by additional clinical data showing similar outcomes.
In a real-world study, semaglutide users lost 5.1% of their baseline weight after one year, while liraglutide users lost 2.2%. Factors such as medication persistence, higher doses, and female gender were linked to better success rates.
| 💡 Did you know? Wegovy consistently produces greater weight loss and improved metabolic results. In the SELECT trial, people taking semaglutide saw weight loss continue for 65 weeks, with effects sustained for up to four years. The average long-term reduction was 10.2%, compared to 1.5% in the placebo group. Wegovy also improved waist circumference, waist-to-height ratio, and cardiovascular risk markers across all BMI categories. Wegovy’s extended activity, combined with easier dosing, contributes to its stronger and longer-lasting outcomes. |
Saxenda’s efficacy for weight loss
According to a meta-analysis of seven randomized controlled trials involving over 6,000 participants, liraglutide 3.0 mg significantly reduced weight by about 4.81% compared to placebo.
However, more people discontinued treatment due to side effects, especially gastrointestinal issues.
One long-term study further supported Saxenda’s benefits. After five years of continuous use, participants lost about 5 kg on average and saw improvements in blood sugar levels and fasting glucose. These benefits were stronger in women and those with higher baseline BMI.
Long-term maintenance and durability
Long-term weight maintenance is challenging, but both medications have shown durable effects when continued.
The STEP 5 trial, as mentioned above, demonstrated that people taking Wegovy kept off a significant portion of their weight for two years, with about 1/3 maintaining at least 20% weight loss.
Saxenda also supports long-term benefits, though on a smaller scale.
In the 5-year liraglutide study, consistent treatment led to stable weight reduction and better glucose control over time. However, some participants still experienced cardiovascular risks, showing that sustained care and monitoring remain important.
Impact of continuity and adherence
Persistence plays a major role. The same study above found that patients who maintained continuous access to medication achieved 5.5% average weight loss, while those who stopped early saw less than 2%. Medication coverage and consistent dosing were key predictors of success.
However, real-world data reveal challenges. The Blue Shield report found that over half of users discontinued either Saxenda or Wegovy within 12 weeks, and nearly 30% quit before even reaching their full therapeutic dose. Many stopped before realizing any meaningful benefit.
Why people stop treatment
There are many barriers to continuing treatment, including side effects, limited access, and social stigma.
Some people face insurance restrictions or difficulty obtaining the drugs due to high demand. Experts have noted that obesity is a chronic condition, and like blood pressure or cholesterol, managing it often requires long-term medication to maintain progress.
Stopping too soon can lead to weight regain and a return of health risks.
Practical considerations & safety
Both Wegovy and Saxenda commonly cause early GI side effects and share serious risks like pancreatitis and a thyroid-tumor warning, making them unsafe for people with certain medical, pregnancy, or mental-health conditions.
Common and serious side effects
Both Saxenda and Wegovy are associated with gastrointestinal side effects such as:
- nausea
- diarrhea
- vomiting
- constipation
- abdominal discomfort
These tend to appear early and fade as the body adjusts. The STEP 1 study above showed that nausea and diarrhea were the most common side effects of Wegovy. Saxenda users were more likely to stop treatment due to similar symptoms.
Other possible risks include:
- acute pancreatitis
- gallbladder disease
- hypoglycemia
- increased heart rate
- kidney injury
- mood changes
Both carry the FDA’s boxed warning about potential thyroid C-cell tumors found in animal studies. People with a personal or family history of thyroid cancer, or with multiple endocrine neoplasia syndrome type 2, should not use these medications.
Who should avoid Saxenda or Wegovy
Certain groups should avoid GLP-1 medications altogether. These include individuals who:
- Have a personal or family history of thyroid cancer
- Are pregnant or planning pregnancy within two months
- Are breastfeeding
- Have had severe allergic reactions to the drug or its ingredients
- Have suicidal thoughts or mental health conditions that could worsen
- Have severe gastrointestinal diseases like gastroparesis
Additionally, those using diabetes medications such as glyburide or glipizide may face a higher risk of low blood sugar, so their other doses may need adjustment.
| 🩺 Doctor’s note Medication alone is not enough. Both drugs are most effective when paired with diet and exercise, as proven in clinical trials. Programs like the National Diabetes Prevention Program have shown that lifestyle changes, combined with medications, can cut the risk of type 2 diabetes by 58%, or even more in older adults. |
Final thoughts
Wegovy stands out as the stronger choice for long-term weight control.
You see this in its larger weight drops, its steady results over many months, and its simple weekly dosing.
Saxenda can still help, yet its daily schedule, smaller average weight loss, and higher dropout rates make progress harder to keep. So what does this mean for you? It shows that lasting success depends on picking the option with the most durable effect, while also thinking about side effects, access issues, lifestyle habits, and health needs.
FAQs on Saxenda vs Wegovy for long term weight loss
Why does Wegovy work better than Saxenda?
Wegovy uses a stronger form of semaglutide, which helps control appetite more effectively. Because of this, people often see bigger and faster weight loss compared to Saxenda.
Which weight-loss injection gives the best results?
Right now, tirzepatide (Zepbound/Mounjaro) shows the greatest average weight loss. Wegovy comes next, followed by Saxenda. Your best option depends on your health history and what your doctor recommends.
Can Wegovy cause hives?
Yes. Some people get mild allergic reactions like rash, itching, or hives. More serious symptoms—like swelling of the face or trouble breathing—need urgent medical care.
How much weight can you lose on Saxenda in 3 months?
Most people lose about 1–2 pounds per week. By 3 months, that’s usually 12–24 pounds if you reach the full daily dose and follow a lower-calorie diet.
Can I switch from Saxenda to Wegovy?
Yes. If you’re on the full 3 mg Saxenda dose, you can switch to Wegovy 0.5 mg weekly. This lower starting dose helps reduce nausea and other side effects.
Can you lose 20 pounds in 3 months on Wegovy?
Possibly. Many people lose more than 5% of their body weight in 3 months. If you weigh around 200 pounds, that’s 10 pounds or more. Some lose up to 20 pounds, but results vary.
What is the strongest prescription weight-loss medication?
Tirzepatide (Zepbound) currently leads with an average weight loss of about 22.5%. Wegovy follows at about 15%, and Saxenda averages around 8%.
Can I skip a week of Wegovy?
Missing one week usually isn’t a big deal. You might feel hungrier, but it won’t ruin your progress. Don’t take a double dose. If you miss more than one week, ask your doctor how to restart.
Sources
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F.; STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
- Gasoyan, H., Pfoh, E. R., Schulte, R., et al. (2024). One-year weight reduction with semaglutide or liraglutide in clinical practice. JAMA Network Open, 7(9), e2433326. https://doi.org/10.1001/jamanetworkopen.2024.33326
- Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., Hovingh, G. K., Jeppesen, O. K., Kokkinos, A., Lincoff, A. M., Meyhöfer, S. M., Oral, T. K., Plutzky, J., van Beek, A. P., Wilding, J. P. H., & Kushner, R. F. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 30, 2049–2057. https://doi.org/10.1038/s41591-024-03025-z
- Lin, Q., Xue, Y., Zou, H., Ruan, Z., Ung, C. O. L., & Hu, H. (2022). Efficacy and safety of liraglutide for obesity and people who are overweight: A systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology, 15(12), 1461–1469. https://doi.org/10.1080/17512433.2022.2130760
- Mirabelli, M., Chiefari, E., Caroleo, P., Arcidiacono, B., Corigliano, D. M., Giuliano, S., Brunetti, F. S., Tanyolaç, S., Foti, D. P., Puccio, L., & Brunetti, A. (2020). Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes. International Journal of Environmental Research and Public Health, 17(1), 207. https://doi.org/10.3390/ijerph17010207
Author Bio: Dr. Adrian Blackwell is the founder and CEO of PonteVita Rx, a telehealth practice dedicated to making medication access simpler, more affordable, and less stressful. Licensed to practice medicine in all 50 states and DC, Dr. Blackwell is board certified in obesity medicine and emergency medicine. He combines clinical expertise with personal experience navigating the healthcare system as a patient and parent to children with chronic illnesses. His mission: ensure everyone has access to their necessary medications without unnecessary barriers.
Medical Disclaimer: All the information here, on these videos, YouTube, social media, or in any other format, is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult your personal physician or other qualified health provider with any questions you may have regarding a medical condition. Never replace professional medical advice given to you personally or delay in seeking it because of something you have read or heard on this website. This information is not meant to diagnose, treat, or cure any medical condition. No patient-physician relationship is formed. If you’re my patient, please text me before you make any changes to your medication. If you believe you are having a medical emergency please call 911.